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Objectives: The relationship between resource utilisation and patient phenotype 
in type 2 diabetes (T2D) is not well characterised. This study aimed to assess fac-
tors associated with weight gain (WG) and the occurrence of hypoglycaemia in 
T2D patients managed with metformin plus sulfonylurea (M+S) and any associated 
impact upon hospital resource utilisation. MethOds: The study was a retrospec-
tive cohort study using the UK Clinical Practice Research Datalink (CPRD) and the 
Hospital Episode Statistics (HES) database. The association between phenotypic 
factors at baseline (therapy escalation from metformin to M+S) with WG (> 2kg 
weight change over 12 months) and presence of any recorded hypoglycaemia over 
12 months following therapy escalation was assessed using logistic regression. 
Hospitalisation associated with increasing body mass index (BMI) and hypoglycae-
mia was also assessed. Results: A total of 11,071 patients met the study inclusion/
exclusion criteria. WG was observed in 28.35% of patients and was significantly 
associated with baseline age (OR= 0.99), female gender (OR= 0.87), baseline weight 
(OR= 1.003) and HbA1c (OR= 1.06). Hypoglycaemia occurred in 1.3% of patients and 
was significantly associated with duration of diabetes (OR= 1.04), baseline HbA1c 
(OR= 0.86) and prior complications status (OR= 1.92). Hospitalisation occurred in 10% 
of patients and was significantly associated with BMI (OR= 1.02) but not hypoglycae-
mia. The mean number of hospital admissions over the follow-up period was 1.7, 1.8, 
1.9 and 3.1 in those with BMIs at the time of admission in the normal, overweight, 
obese and morbidly obese categories respectively. cOnclusiOns: This real-world 
observational analysis suggests there are identifiable phenotypic characteristics 
predictive of WG and hypoglycaemia. This study also shows a general relationship 
between increasing BMI and hospitalisation that may not be adequately captured 
in widely used vascular risk equations such as UKPDS in which BMI has minimal 
influence on risk. Consequently, the value of diabetes management strategies that 
minimise WG may be underestimated.
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Objectives: Frequency of self-monitoring of blood glucose (SMBG) varies in 
patients with type 2 diabetes mellitus (T2DM) and there is debate as to the true 
benefit it plays in the management of the condition. The aim of this study was to 
compare the frequency of SMBG using patient medication record (PMR) dispensed 
data, with self-reported data, and to assess the relationship between type of glu-
cose-lowering therapy to SMBG frequency among patients with T2DM dispensed 
glucose test strips. MethOds: Patients with T2DM were identified in community-
pharmacies (n= 116) using PMRs in 2012. Patients who consented to participation 
were surveyed in a face-to-face interview where self-reported (SR) frequency 
of SMBG was determined. Dispensed data were classified by the mechanism of 
action of the blood glucose lowering regimen, (secretagogues vs. sensitisers). Test 
strip use over a 12 month period was calculated and compared to SR use from 
the patient survey. Analysis was performed in MS Excel® and SAS®. Results: 
Data from 484 patients were analysed (mean age 65yrs). Sensitising agents alone 
accounted for 45% of the cohort, secretagogues alone - 8%, a combination of both 
- 42%, and diet 5%. Approximately 52% of patients reported frequency of SMBG as 
once or twice daily vs 56% in the dispensed data. 13% of patients reported a fre-
quency of at least 3 times daily vs 21% for PMR data. There was no statistically sig-
nificant difference in SR frequency among those on the various glucose-lowering 
regimens. No correlations were found between frequency of use and age, gender, 
place of residence or number of prescribed medicines. cOnclusiOns: Results 
from this study highlight (i) differences in frequency of blood glucose monitoring 
between dispensed data and SR data and (ii) the difficulty in accurately capturing 
this type of data. A reliance on either type of data alone may be insufficient to 
accurately inform decision making.
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Objectives: Hypoglycaemia is common in diabetic patients, often as a side effect 
of a treatment. Its occurrence can influence patients’ professional life and gener-
ate extra direct costs to the health care system. Severe (requiring another person’s 
assistance) hypoglycaemic events (SHEs), especially leading to hospitalisation, are 
associated with the highest burden and for that reason their real frequency and 
costs should be calculated properly. The aim of the study was to assess the accuracy 
of reporting of hypoglycaemia to the National Health Fund in Poland. MethOds: 
A combination of prospective and retrospective designs was applied. A detailed 
retrospective analysis of 117 hospitalised patients’ case histories was performed 
from the period of February-March 2013. In addition, prospectively, in March and 
April 2013, 45 patients were interviewed and their clinical records were analysed. 
Information was collected in special case report forms. Real hospitalisation costs 
were also calculated. Results: In the retrospective arm hypoglycaemia affected 42 
patients (55% of type 1 and 25% of type 2) and 85 SHEs were recorded. Only 2 patients 
were reported in the hypoglycaemia DRG group compared to a broader diabetes/
hyperglycaemia DRG group, where the financing level is higher. A financial differ-
ence equal to 7,082 EUR was generated due to more favourable classification of these 
cases. In the prospective arm 20 patients experienced hypoglycaemia, whereas only 
one was coded as hypoglycaemic. It has generated 2,247 EUR difference. Even with 
this financially more favourable, (still clinically justified but less precise) coding 
hypoglycaemic patients generated losses equal to 23,628 EUR in retrospective and 
5,053 EUR in prospective group. cOnclusiOns: Our study provided a direct proof 
association with the probability of seeing an endocrinologist: rates of specialist 
visits are the largest under the age of 25 (p< 0.05). In addition, people treated with 
insulin and those with another endocrine disorder are more likely to see a special-
ist (p< 0.001). In contrast, the newly diagnosed and patients followed by a general 
practitioner (GP) present lower probabilities of specialist visits (p< 0.001). Moreover, 
the probability of specialist visit rises when the density of endocrinologists is large 
in the patients’ neighbourhood, while it decreases with the distance (in kilome-
tres) from the patients’ house to the endocrinologist’s office. Finally, the chances 
of seeing a specialist increase with income and decrease as the cost for a visit 
rises. cOnclusiOns: Our results are consistent with previous literature showing 
evidence of the existence of a substitution effect between GPs and specialists in 
diabetes care. We show that financial barriers exist even in a population of patients 
receiving national health insurance coverage.
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Objectives: Severe hypoglycemic events (SHE) contribute to health care utiliza-
tion for insulin-dependent diabetics, and may drive expenditures by health care 
payers. Rescue treatment for SHE includes glucagon kits, which are administered 
by caregivers and difficult to use. Consequently, there are high rates of unsuccess-
ful administration, leading to increased health care service use. A new kit under 
development aims to ease the burden of administration by reducing the complex-
ity. The new device aims to increase successful use and lower rates of health care 
service utilization. This study aimed to understand payers’ receptivity to this value 
proposition. MethOds: Seven medical directors from US payers were interviewed, 
representing commercial, Medicare, Medicaid and other covered lives. The interview 
was designed to understand plans’ focus on diabetes and hypoglycemia, cover-
age/reimbursement of current kits, and impressions of characteristics of the new 
kit. Results: The prevention of SHE is not a concern for insurers; the risk of SHE 
is largely a type 1 problem, representing a small subset of their overall diabetic 
population. While payers are confident in current kits’ effectiveness, they are not 
focused on managing access to such a low-volume treatment. Current kits are cov-
ered by insurers without restrictions, and contracting is not prevalent due to low 
volume. Payers believe the new kit will be an improvement over current kits, but do 
not believe it will reduce the cost of SHE. cOnclusiOns: Payers feel that the new 
kit will be an improvement over currently available kits, but are skeptical that the 
ease of use will translate into lower health care service use. Additionally, SHE is not 
a major cost driver among their diabetic population; therefore, SHE is not a high-
priority condition. Consequently, for optimal market access and reimbursement, the 
new kit must demonstrate significant reductions in high-cost health care utilization 
(e.g., ED, hospitalizations) to justify a premium price without coverage restrictions.
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Objectives: The primary objective was to assess the impact of using ‘metformin 
plus sulphonylureas’ (Met+SU) in comparison with ‘metformin plus other oral 
anti-hyperglycaemic agents’ (Met+OHA) in patients with Type 2 Diabetes (T2D) 
on diabetes-associated secondary health care utilisation in the UK. The second-
ary objectives included investigating individual components of the primary objec-
tive. MethOds: This retrospective cohort study used data from the Clinical Practice 
Research Datalink (CPRD) linked to Hospital Episodes Statistics. Adults (≥ 40 years) 
with T2D initiated on dual therapy with Met+SU or Met+OHA following metformin 
monotherapy were identified during the period April 2003–March 2012 and com-
prised the two study cohorts. Propensity scores were estimated and Met+SU patients 
caliper matched to Met+OHA patients to balance the covariates (including HbA1C 
and duration of diabetes at baseline). Diabetes-associated secondary health care 
utilisation (inpatient admissions and outpatient visits) were measured from > 6 
months post-initiation of dual therapy until treatment change or end of follow-up. 
Outcomes were calculated as rate ratios (RR), adjusted for over dispersion using 
negative binomial regression and propensity score for covariates. Results: 14,416 
patients in total were identified and in the directly matched analysis, 1,704 patients 
were included in each cohort. For the primary objective, the Met+SU cohort had a 
numerically higher rate of diabetes-related secondary health care utilisation than 
Met+OHAs (adjusted RR 1.12, 95% confidence interval [95%CI]: 0.97-1.29). For the 
secondary endpoints examining individual components, the adjusted RR for Met+SU 
cohort for inpatient admissions was 1.34 (95%CI 0.92–1.96) and 1.10 (95%CI 0.95-1.28) 
for outpatient visits. Macrovascular complications, accounting for 68.7% of inpa-
tient admissions, occurred at a significantly higher rate in the Met+SU cohort than 
Met+OHA (adjusted RR 1.77, 95%CI: 1.15-2.71). cOnclusiOns: Glucose-lowering 
combination therapy with metformin plus sulphonylurea is associated with a direc-
tionally higher rate of secondary health care utilisation than metformin plus other 
oral anti-hyperglycaemic agents.
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